Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.
Volume: 35, Issue: 15_suppl, Pages: 4006 - 4006
Published: May 20, 2017
Abstract
4006 Background: Despite improvements in multidisciplinary management, BTC has a poor outcome. Approximately 20% of cases are suitable for surgical resection with a 5 year survival of < 10%. BILCAP aimed to determine whether capecitabine (Cape) improves overall survival (OS) compared to observation (Obs) following radical surgery. Methods: Patients with completely-resected cholangiocarcinoma (CCA) or gallbladder cancer (including liver and...
Paper Details
Title
Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.
Published Date
May 20, 2017
Journal
Volume
35
Issue
15_suppl
Pages
4006 - 4006
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History